Edition:
United States

Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

12.35USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$12.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
33,128
52-wk High
$12.35
52-wk Low
$3.38

Chart for

About

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads... (more)

Overall

Beta: -0.01
Market Cap(Mil.): $371.03
Shares Outstanding(Mil.): 30.04
Dividend: --
Yield (%): --

Financials

  CTSO.OQ Industry Sector
P/E (TTM): -- 38.09 34.18
EPS (TTM): -0.35 -- --
ROI: -75.07 8.73 13.17
ROE: -159.26 12.61 15.15

BRIEF-Cytosorb Adds Bilirubin And Myoglobin Reduction To Eu Approved Indications For Use

* CYTOSORB® ADDS BILIRUBIN AND MYOGLOBIN REDUCTION TO EUROPEAN UNION APPROVED INDICATIONS FOR USE

May 14 2018

BRIEF-CytoSorbents Reports Qtrly Loss Per Share $0.10

* CYTOSORBENTS REPORTS STRONG FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

BRIEF-Cytosorbents Enrolls First Patient Into Pivotal U.S. Refresh 2-AKI Trial

* CYTOSORBENTS ENROLLS FIRST PATIENT INTO PIVOTAL U.S. REFRESH 2-AKI TRIAL USING CYTOSORB® DURING COMPLEX CARDIAC SURGERY Source text for Eikon: Further company coverage:

Apr 24 2018

BRIEF-Cytosorbents Refinances Existing Debt With New $15 Mln Debt Facility With Bridge Bank

* CYTOSORBENTS REFINANCES EXISTING DEBT WITH NEW $15 MILLION DEBT FACILITY WITH BRIDGE BANK

Apr 04 2018

BRIEF-Cytosorbents Achieves Record Revenue And Product Sales Growth In 2017

* CYTOSORBENTS ACHIEVES RECORD REVENUE AND PRODUCT SALES GROWTH IN 2017

Mar 08 2018

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

Feb 15 2018

BRIEF-Cytosorbents Sees Q4 2017 Revenue About $4.6 Million

* CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER

Jan 08 2018

BRIEF-U.S. FDA Approves Cytosorbents' Refresh 2 IDE Application With Conditions

* CYTOSORBENTS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE U.S. REFRESH 2 PIVOTAL CARDIAC SURGERY TRIAL IDE APPLICATION

Dec 21 2017

Earnings vs. Estimates